Sugi Predict

Sugi Predict / Compounds / SCHEMBL5207916

SCHEMBL5207916

SCHEMBL5207916

COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccccc4C)c(Cl)c3)c2cc1OC

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 20/20 0.78
▸ PDGFRA P16234 15/20 0.78
▸ FLT1 P17948 3/20 0.73
▸ FLT4 P35916 3/20 0.73
▸ MET P08581 3/20 0.73
▸ KIT P10721 3/20 0.73
▸ EPHB2 P29323 2/20 0.73
▸ RIPK2 O43353 2/20 0.73
▸ STK10 O94804 2/20 0.73
▸ ABL1 P00519 2/20 0.73
▸ RET P07949 2/20 0.73
▸ PDGFRB P09619 2/20 0.73
▸ BCR P11274 2/20 0.73
▸ FGFR1 P11362 2/20 0.73
▸ SLC6A3 Q01959 2/20 0.73
▸ DDR1 Q08345 2/20 0.73
▸ MAP4K2 Q12851 2/20 0.73
▸ PTK6 Q13882 2/20 0.73
▸ DDR2 Q16832 2/20 0.73
▸ AURKB Q96GD4 2/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5202130 0.92 KDR (0.78) KDRPDGFRAFLT1FLT4MET
SCHEMBL5207822 0.89 KDR (0.70) KDRPDGFRAFLT1FLT4MET
SCHEMBL5204741 0.89 KDR (0.85) KDRPDGFRAFLT1FLT4MET
SCHEMBL7485134 0.87 PDGFRA (1.00) KDRPDGFRAKIT
SCHEMBL5204147 0.87 KDR (0.84) KDRPDGFRAFLT1FLT4MET
SCHEMBL5205592 0.86 KDR (0.69) KDRPDGFRAFLT1FLT4MET
Hydrochloric Acid SCHEMBL5202398 0.86 KDR (0.82) KDRPDGFRAFLT1FLT4MET
SCHEMBL1660426 0.86 KDR (0.82) KDRPDGFRAFLT1FLT4MET
SCHEMBL1659143 0.86 KDR (0.79) KDRPDGFRAFLT1FLT4MET
SCHEMBL5205475 0.85 KDR (0.74) KDRPDGFRAFLT1FLT4MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1384712-B1 Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity KIRIN BREWERY (JP) 2007-03-07 — — EP disclosed
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-02-01 — — US disclosed
US-7169789-B2 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2007-01-30 — — US disclosed
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 2004-10-21 — — US disclosed
EP-1153920-B1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BREWERY (JP) 2003-10-29 — — EP disclosed
EP-1153920-A1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES KIRIN BEER KABUSHIKI KAISHA (JP) 2001-11-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027318-A1 Quinoline derivatives and quinazoline derivatives CYTH3, NQO2, NRAS KDR 2466/4885PDGFRA 3108/4885FLT1 2419/4885
US-20040209905-A1 Quinoline derivatives and quinazoline derivatives RABL3, NRAS, CYTH3 KDR 3106/4885PDGFRA 3103/4885FLT1 3437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.